After proving the completeness data entry was made by using Epi-data 4.2.00 and SPSS version 20.0 statistical software was used for cleaning, coding, recoding, and analysis. Descriptive statistics of patients’ demographic and clinical characteristics were reported in the text, tables, and graphs. The time variable and age of the patients were not normally distributed continuous variables. As a result, we summarized by their median and interquartile range (IQR). The null hypothesis (Ho) states that the distribution of time and the treatment outcomes among DR-TB are the same across categories of DR-TB genotypic diagnosis algorisms and the Alternative Hypothesis (Ha) was stated that the distribution of time and the treatment outcome of DR-TB are different across categories of DR-TB genotypic diagnosis algorisms. To test the hypothesis (the existence of time difference from: a first care-seeking visit to diagnosis, diagnosis to treatment start, and first care-seeking visit to treatment start among DR-TB diagnostic algorisms) we used the Independent Sample Kruskal-Wallis Test. And to determine the presence of a statistically significant association between categories (DR-TB diagnostic algorism groups and the treatment outcome), we used Pearson’s chi-square (X2) or Fisher exact test, where appropriate. The P-value was calculated and the result was considered statistically significant when it was < 0.05.

Ethical Clearance. The Ethical Review Committee of the University of Gondar approved the study. A permission and support letter were also obtained from the Amhara public health institutions, the management committee of each hospital, and TB ward heads. Thus, informed consent was waived as we received the institutional support letter. Information obtained at any course of the study was kept confidential. The data were anonymized and personal identifiers were not included and secured via password in computerized databases to ensure confidentiality. The results of this study were made accessible to clinicians for decision-making as early as available.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.